Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BP1001-A |
| Synonyms | |
| Therapy Description |
Limited information is currently available on BP1001-A, a putative liposomal anti-Grb2 antisense oligonucleotide (Jun 2024). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BP1001-A | BP-1001-A|BP 1001-A | Limited information is currently available on BP1001-A, a putative liposomal anti-Grb2 antisense oligonucleotide (Jun 2024). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04196257 | Phase I | BP1001-A BP1001-A + Paclitaxel | BP1001-A in Patients With Advanced or Recurrent Solid Tumors | Recruiting | USA | 0 |